Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases, with an emphasis on oncology and immunology. The company’s research programs are designed to address biological pathways involved in tumor growth, disease progression and immune regulation.

Corbus’ oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an investigational monoclonal antibody that targets integrins involved in tumor biology and the tumor microenvironment. The company has also advanced earlier immunology programs, including lenabasum, an oral cannabinoid receptor type 2 agonist that was investigated in inflammatory and fibrotic diseases.

Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus conducts research and clinical development activities through its U.S. operations and collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has guided Corbus through its strategic expansion into oncology.

Key Stats

• Today's Range: $5.65 to $6.00
• 50-Day Range: $5.85 to $11.48
• 52-Week Range: $5.65 to $20.56
• Volume: 415,941 shs
• Average Volume: 467,553 shs
• Market Capitalization: $107.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.00
• Consensus Rating: Moderate Buy

Corbus Pharmaceuticals Stock Analysis - MarketRank™

Corbus Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 330th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Corbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Corbus Pharmaceuticals has a consensus price target of $41.00, representing about 620.3% upside from its current price of $5.69.

Amount of Analyst Coverage

Corbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($5.62) to ($6.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Corbus Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Corbus Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Corbus Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.31% of the float of Corbus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 1.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Corbus Pharmaceuticals has recently increased by 22.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Corbus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Corbus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.34

News Sentiment

Corbus Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

15 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Corbus Pharmaceuticals insiders have sold 1,130.13% more of their company's stock than they have bought. Specifically, they have bought $25,038.00 in company stock and sold $308,000.00 in company stock.

Percentage Held by Insiders

3.50% of the stock of Corbus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRBP
• CIK: 1595097
• Web: www.corbuspharma.com
• Phone: (617) 963-0100
• Fax: 617-663-6085
• Employees: 36
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Corbus Pharmaceuticals: $41.00
• High Price Target: $53.00
• Low Price Target: $30.00
• Potential Upside/Downside: +612.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.05%
• Return on Assets: -74.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.71
• Quick Ratio: 5.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.40 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 18,671,000
• Free Float: 18,018,000
• Market Cap: $107.45 million
• Optionable: Optionable
• Beta: 2.63